NeuroSense Therapeutics Ltd. - Ordinary Shares (NRSN)

$1.34 0.02 (1.47%)

16:00 EDT NRSN Stock Quote Delayed 30 Minutes

NRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023

By InvestorPlace Earnings Apr 5, 2024

NRSN stock results show that NeuroSense Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

More Articles

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 132,972

Day's Range $1.30 - $1.50

52-Week Range $0.40 - $2.33

Dividend & Yield N/A (N/A)

NRSN Stock Predictions, Articles, and NeuroSense Therapeutics Ltd. - Ordinary Shares News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Nov 17, 2023

It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Jan 20, 2023

It's the final day of trading this week and we're checking in on the biggest pre-market stock movers for Friday morning!

Why Is NeuroSense (NRSN) Stock Up 98% Today?

By William White, InvestorPlace Writer Jan 19, 2023

NeuroSense (NRSN) stock is taking off on Thursday as investors react to data from a biomarker study concerning Alzheimer's disease (AD).

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Nov 16, 2022

Pre-market stock movers are a hot topic among traders this morning as we cover all of the biggest news moving shares on Wednesday!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Jul 6, 2022

We're starting off Wednesday with a breakdown of the biggest pre-market stock movers for investors to keep an eye on today!

Why Is NeuroSense (NRSN) Stock Up 35% Today?

By David Moadel, InvestorPlace Contributor Jun 30, 2022

NRSN stock is on the move in the wake of encouraging clinical results for a novel drug combination to treat Alzheimer's disease.

NeuroSense Therapeutics (NRSN) Stock Pops on Positive ALS Study Results

By David Moadel, InvestorPlace Contributor Jun 27, 2022

NRSN stock is getting plenty of attention today and a bid to the tune of more than 70% in the wake of positive clinical results.

Why Is NeuroSense Therapeutics (NRSN) Stock Up 300% Today?

By Samuel O'Brient, InvestorPlace Reporter Mar 21, 2022

A thumbs up from the FDA has NRSN stock surging. Here's what this victory means for NeuroSense and for investors.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer Feb 28, 2022

We've got another busy week of trading ahead of us so let's start it off with the biggest pre-market stock movers for Monday!

NeuroSense Therapeutics gets notice from Nasdaq (NASDAQ:NRSN)

From Seeking Alpha Dec 27, 2023

NeuroSense Therapeutics receives notice from Nasdaq regarding failure to meet minimum stockholders' equity requirement.

NeuroSense ALS candidate meets key study goals (NASDAQ:NRSN)

From Seeking Alpha Dec 5, 2023

NeuroSense's lead drug candidate, PrimeC, achieves primary safety and tolerability endpoints in a Phase 2b ALS trial, showing potential for disease...

NeuroSense ends equity offering, says it's fully funded into Q2 2024 (NRSN)

From Seeking Alpha Oct 2, 2023

NeuroSense terminates its equity offering program, with the company now fully funded into Q2 2024 and past the anticipated release of Phase 2b data for its ALS drug PrimeC.

NeuroSense Therapeutics prices $4.5M stock and warrants offering (NASDAQ:NRSN)

From Seeking Alpha Jun 22, 2023

NeuroSense Therapeutics (NRSN) priced a public offering of common shares and a concurrent private placement of warrants to raise $4.5 million, the company said Thursday

NeuroSense stock rises on deal with Biogen for ALS drug (NASDAQ:NRSN)

From Seeking Alpha Jun 13, 2023

NeuroSense Therapeutics (NRSN) announced a deal with Biogen (BIIB) on Tuesday to run a biomarker study to evaluate its lead asset PrimeC in ALS. Read more here.

Maxim Group Sticks to Their Buy Rating for Neurosense Therapeutics Ltd. (NRSN)

From TipRanks Dec 2, 2022

In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Neurosense Therapeutics Ltd. (NRSN – Research Report), with ...

ADVERTISEMENT